CAR-T cell therapy revs up in Europe
Ever since reports that blood cancer response rates to T cells carrying chimeric antigen receptors (CARs) exceeded 80%, investors have been betting big on CAR-T cell approaches. In August, the first two therapies hit European markets in a head-to-head race to be the number one next-gen cancer therapy. But will CAR-T cell treatments lead the pack long term? Or will alternatives like TCR-based cell therapy or multivalent bispecific antibody-T cell engagers leave them in the dust?
In this issue:
- Modern breeding: How the ECJ ruling on genome editing thwarts organic farming
- DNA synthesis: Can a new enzyme approach help solve global problems?
- Photosynthesis: Engineers converge on the Holy Grail of energy production
- CROs & CDMOs: New technologies that trigger pharma outsourcing growth
- Interviews with Adi Hoess, CEO, Affimed NV; Günter Huhle, Johnson & Johnson Innovation, JLABS EMEA, Beerse; Sebastian Sødergren, Vice President of New Business Development, Incubation & Acquisitions, Novozymes
- News from our partner associations Swiss Biotech Association, Medtec Europe and EuropaBio.
Industry criticises EPO plans
Concerns raised by life sciences stakeholders regarding the European Patent Office’s Early Certainty in Examination project can no longer be...
Microfluidics: Mapping DNA-binders
A patent on microfluidics-based ligand enrichment followed by sequencing has been filed, and the group, headed by Bart Deplancke, aims to...
A clear path ahead for the bioeconomy
European Biotechnology Matti, you say we need to stop using fossil fuels. But right now there hardly seems to be a consensus on that –...